Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment. (PubMed, Am J Hematol) - Sep 16, 2026 - "The use of chemo-immunotherapy combining cladribine (CDA) and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus R, MEK inhibitors (MEKi), Bruton Tyrosine Kinase inhibitors (BTKi) and/or Bcl-2 inhibitors (Bcl-2i). The optimal sequence of the different treatments remains to be determined."
IO biomarker • Journal • Diffuse Large B Cell Lymphoma • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • ANXA1 • CD123 • IGH • IL2RA • IL3RA • ITGAE • ITGAX • TP53
|
|
Elsa Maitre; Jérôme Paillassa; Xavier Troussard
|